1. Home
  2. ALT vs ATXS Comparison

ALT vs ATXS Comparison

Compare ALT & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALT
  • ATXS
  • Stock Information
  • Founded
  • ALT 1997
  • ATXS 2008
  • Country
  • ALT United States
  • ATXS United States
  • Employees
  • ALT N/A
  • ATXS N/A
  • Industry
  • ALT Biotechnology: Pharmaceutical Preparations
  • ATXS Biotechnology: Pharmaceutical Preparations
  • Sector
  • ALT Health Care
  • ATXS Health Care
  • Exchange
  • ALT Nasdaq
  • ATXS Nasdaq
  • Market Cap
  • ALT 472.3M
  • ATXS 401.2M
  • IPO Year
  • ALT N/A
  • ATXS 2015
  • Fundamental
  • Price
  • ALT $4.55
  • ATXS $4.04
  • Analyst Decision
  • ALT Strong Buy
  • ATXS Strong Buy
  • Analyst Count
  • ALT 8
  • ATXS 5
  • Target Price
  • ALT $21.00
  • ATXS $26.60
  • AVG Volume (30 Days)
  • ALT 2.2M
  • ATXS 369.7K
  • Earning Date
  • ALT 05-08-2025
  • ATXS 05-08-2025
  • Dividend Yield
  • ALT N/A
  • ATXS N/A
  • EPS Growth
  • ALT N/A
  • ATXS N/A
  • EPS
  • ALT N/A
  • ATXS N/A
  • Revenue
  • ALT $20,000.00
  • ATXS N/A
  • Revenue This Year
  • ALT N/A
  • ATXS N/A
  • Revenue Next Year
  • ALT N/A
  • ATXS N/A
  • P/E Ratio
  • ALT N/A
  • ATXS N/A
  • Revenue Growth
  • ALT N/A
  • ATXS N/A
  • 52 Week Low
  • ALT $3.55
  • ATXS $3.56
  • 52 Week High
  • ALT $11.16
  • ATXS $12.92
  • Technical
  • Relative Strength Index (RSI)
  • ALT 43.21
  • ATXS 28.96
  • Support Level
  • ALT $4.32
  • ATXS $3.56
  • Resistance Level
  • ALT $4.75
  • ATXS $4.39
  • Average True Range (ATR)
  • ALT 0.38
  • ATXS 0.42
  • MACD
  • ALT 0.05
  • ATXS -0.04
  • Stochastic Oscillator
  • ALT 63.22
  • ATXS 22.61

About ALT Altimmune Inc.

Altimmune Inc is engaged in developing treatments for obesity and liver diseases. The Company's pipeline includes next-generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines.

About ATXS Astria Therapeutics Inc.

Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.

Share on Social Networks: